Search Results - "Almohamad, W"

FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC) by Ulusakarya, A., Karray, W., Abdou, J., Karaboué, A., Haydar, M., Krimi, S., Gumus, Y., Almohamad, W., Goldschmidt, E., Biondani, P., Morère, J.F.

Get full text

Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma by Machover, D, Delmas-Marsalet, B, Misra, S.C, Ulusakarya, A, Gumus, Y, Frénoy, N, Guettier, C, Saffroy, R, Innominato, P, Almohamad, W, Brahimi, N, Haydar, M, Goldschmidt, E

“…Abstract Background We explored the addition of rituximab to high-dose cytarabine (ara-C), oxaliplatin (L-OHP), and dexamethasone [R-DHAOx], in resistant and…”
Get full text

761PFOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC) by Ulusakarya, A, Karray, W, Abdou, J, Karaboué, A, Haydar, M, Krimi, S, Gumus, Y, Almohamad, W, Goldschmidt, E, Biondani, P, Morère, J F

Get full text

Medico-pharmaceutical approach to reduce costs of infusion-related reactions (IRR) associated with cetuximab at Paul Brousse hospital by Castagné, V., Goldschmidt, E., Lévi, F., Brahimi, N., Almohamad, W., Machover, D., Karaboué, A., Habert, H., Bonhomme-Faivre, L., Bouchahda, M.

“…Abstract only…”
Get full text